EndoQuest Robotics, a pioneering leader in endoluminal robotic surgical technology, announced it has successfully closed a Series D-2 financing round.

EndoQuest Robotics 是内腔机器人手术技术的先驱领导者，宣布其已成功完成 D-2 轮融资。

This strategic funding will fuel the advancement of EndoQuest's flexible endoluminal surgical platform, supporting the ongoing pivotal PARADIGM clinical trial and accelerating the pathway towards U.S. FDA clearance, as well as early feasibility studies in the upper GI tract and progression of advanced endoluminal visualization technologies in the Company's portfolio.

这笔战略资金将推动EndoQuest柔性腔内手术平台的发展，支持正在进行的关键PARADIGM临床试验，加速获得美国FDA批准的进程，并推动上消化道早期可行性研究及公司产品组合中先进的腔内可视化技术的发展。

.

。

Funding for the round was co-led by Crescent Enterprises and Dr. Fred Moll. Other investors in the round included Puma Venture Capital and The University of Texas Health Science Center at Houston (UTHealth Houston).

本轮融资由新月企业和弗雷德·莫尔博士共同领投。其他参与本轮融资的投资者包括美洲狮风险资本和德克萨斯大学休斯顿健康科学中心（UTHealth Houston）。